Table 2 Patient characteristics and outcomes in the training dataset used to plot Qini curves.
| Â | PVI-alone | PVI-plus | P-value |
|---|---|---|---|
N | 62 | 63 | Â |
Age | 66.00 [59.00, 72.75] | 67.00 [60.00, 73.00] | 0.711 |
Female sex | 16 (25.8) | 18 (28.6) | 0.841 |
Body mass index | 24.71 [22.24, 27.03] | 24.77 [21.68, 26.40] | 0.853 |
Family history of atrial fibrillation | 5 (8.1) | 7 (11.1) | 0.763 |
Long-standing persistent atrial fibrillation | 11 (17.7) | 17 (27.0) | 0.284 |
Hypertension | 34 (54.8) | 37 (58.7) | 0.720 |
Diabetes mellitus | 11 (17.7) | 10 (15.9) | 0.815 |
Dyslipidemia | 32 (51.6) | 29 (46.0) | 0.593 |
Smoking history | 39 (62.9) | 38 (60.3) | 0.855 |
Heart failure | 13 (21.0) | 14 (22.2) | > 0.999 |
Dilated cardiomyopathy | 2 (3.2) | 0 (0.0) | 0.244 |
Hypertrophic cardiomyopathy | 0 (0.0) | 1 (1.6) | > 0.999 |
Sick sinus syndrome | 1 (1.6) | 1 (1.6) | > 0.999 |
Stroke or systemic thromboembolism | 4 (6.5) | 9 (14.3) | 0.241 |
Sleep apnea syndrome | 9 (14.5) | 6 (9.5) | 0.423 |
Thyroid disease | 2 (3.2) | 6 (9.5) | 0.273 |
Chronic obstructive pulmonary disease | 3 (4.8) | 2 (3.2) | 0.680 |
Liver disease | 2 (3.2) | 3 (4.8) | > 0.999 |
History of use of anti-arrhythmic drug | 13 (21.0) | 13 (20.6) | > 0.999 |
Hemoglobin | 14.80 [14.03, 15.60] | 14.20 [13.45, 14.90] | 0.003 |
Brain type natriuretic peptide | 132.20 [91.50, 208.10] | 162.30 [104.70, 239.00] | 0.258 |
Creatinine | 0.89 [0.79, 0.99] | 0.88 [0.76, 0.96] | 0.582 |
C-reactive protein | 0.10 [0.07, 0.19] | 0.10 [0.07, 0.19] | 0.924 |
Left ventricular ejection fraction | 62.39 [55.04, 67.48] | 64.04 [56.61, 68.61] | 0.498 |
Left atrial diameter | 41.60 [40.00, 44.20] | 43.20 [39.90, 47.00] | 0.104 |
Mitral regurgitation | 0 (0.0) | 4 (6.3) | 0.119 |
Recurrence of atrial fibrillation | 19 (30.6) | 12 (19.0) | 0.151 |
